Memory Pharmaceuticals Corp., a company focused on neurodegenerative diseases, secured its first licensing agreement, a potential $150 million deal with F. Hoffmann-La Roche Ltd. focused on the development of compounds for Alzheimer's disease. (BioWorld Today) Read More
